Cancer Research
Cancer is a term used to define a group of diseases in which abnormal cells divide without control, are able to invade neighboring tissues/organs and metastasize. Cancer has been characterized by six hallmarks; self sufficiency in proliferative growth signals, insensitivity to growth inhibitors, evasion of apoptosis, limitless replicative potential, ability to develop blood vessels (angiogenesis), and tissue invasion and metastasis.
Cancer Research Products Areas
Products for Cancer Research - Page 77
- Cat.No. Product Name Information/Activity
-
BCC7721
FIPI
FIPI is a derivative of halopemide which potently inhibits both PLD1 and PLD2 with IC50s of 25 nM and 20 nM, respectively.
-
BCC7728
LY 311727
164083-84-5
-
BCC2310
Varespladib (LY315920)
Varespladib (LY315920) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively.
-
BCC6716
OBAA
221632-26-4
-
BCC7074
PACOCF3
Phospholipase A<sub>2</sub> inhibitor
-
BCC5199
U-73122
U-73122 is a phospholipase C (PLC) and 5-LO (5-lipoxygenase) inhibitor with an IC50of 1-2.1 µM for PLC.
-
BCC8091
U 73343
U-73343, an inhibitor of PLC (putative phospholipase C)-dependent processes, is an analog of U-73122 and can be used as a negative control.
-
BCC7715
VU 0155069
VU0155069 (CAY10593), compound 69, is a selective phospholipase D1 (PLD1) inhibitor with an IC50 value of 46 nM in vitro. VU0155069 (CAY10593) strongly inhibits the invasive migration of several cancer cell lines in transwell assays.
-
BCC7875
VU 0364739 hydrochloride
1244640-48-9
-
BCC7396
YM 26734
144337-18-8
